non-Hodgkin lymphoma

non-Hodgkin lymphoma
Name	Non-Hodgkin lymphoma
Field	Hematology, Oncology
Symptoms	Lymphadenopathy, fever, night sweats, weight loss
Complications	Immunodeficiency, infection, organ compression
Onset	Variable
Causes	Chromosomal translocations, viral infection, immunosuppression
Risks	Age, HIV infection, autoimmune disease, chemical exposure
Diagnosis	Biopsy, immunophenotyping, imaging
Treatment	Chemotherapy, immunotherapy, radiation, stem cell transplant
Prognosis	Depends on subtype and stage

non-Hodgkin lymphoma Non-Hodgkin lymphoma is a diverse group of lymphoid malignancies arising from B cells, T cells, or natural killer cells that present with variable clinical courses. It spans indolent entities and aggressive neoplasms, and management draws on hematology, oncology, pathology, and transplantation expertise from centers such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Historical landmarks in characterization involved investigators at institutions connected with the National Cancer Institute and figures associated with the Nobel Prize in Physiology or Medicine.

Classification and Subtypes

Classification relies on morphologic, immunophenotypic, genetic, and clinical features established by entities including the World Health Organization and the International Agency for Research on Cancer. Major B‑cell subtypes include diffuse large B‑cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma; T‑cell and NK‑cell neoplasms include peripheral T‑cell lymphoma, anaplastic large cell lymphoma, and angioimmunoblastic T‑cell lymphoma, categories refined through collaborations among investigators at Harvard Medical School, Johns Hopkins University, University of Oxford, and University of Cambridge. Molecular classifications invoke recurrent chromosomal translocations (for example involving MYC, BCL2, BCL6) studied in laboratories at Cold Spring Harbor Laboratory and the Broad Institute, and incorporated into guidelines from the European Society for Medical Oncology and the American Society of Hematology. Gene expression profiling and next‑generation sequencing efforts at institutions like the Sanger Institute and Institut Pasteur further subdivide groups, affecting therapeutic choices recommended by advisory bodies such as the National Comprehensive Cancer Network.

Signs and Symptoms

Presentation often includes painless lymphadenopathy, systemic "B" symptoms (fever, night sweats, weight loss), and extranodal manifestations such as gastrointestinal obstruction, splenomegaly, or central nervous system involvement. Symptom recognition and referral patterns have been described in cohorts from Mayo Clinic, Karolinska Institute, and Cleveland Clinic, and public awareness campaigns by organizations like the Leukemia & Lymphoma Society and Cancer Research UK aim to shorten diagnostic delay. Physical findings prompting investigation echo case series reported from institutions including Stanford University and University College London, with severe presentations sometimes requiring urgent management at centers such as Bellevue Hospital or Guy's and St Thomas' Hospital.

Causes and Risk Factors

Risk factors encompass advancing age, immunodeficiency states including HIV infection and post‑transplant immunosuppression, autoimmune disorders such as Sjögren syndrome, and environmental exposures including pesticides and solvents, associations explored in epidemiologic studies from the International Agency for Research on Cancer and the World Health Organization. Oncogenic viruses—Epstein–Barr virus, human T‑lymphotropic virus type 1, hepatitis C virus—have causal links detailed in publications from the Centers for Disease Control and the Pasteur Institute. Genetic predisposition and somatic mutations identified through consortia involving the Wellcome Trust and the Cancer Genome Atlas contribute to pathogenesis, while historic occupational cohorts such as those studied by the UK Biobank and Framingham Heart Study have informed exposure risk estimates.

Diagnosis

Definitive diagnosis requires excisional lymph node biopsy with histopathology, immunohistochemistry, flow cytometry, and molecular studies, protocols standardized by pathology departments at institutions like UCLA, Mount Sinai, and Memorial Sloan Kettering. Imaging modalities including computed tomography and positron emission tomography combined with radiology expertise from Massachusetts General Hospital and Guy's Hospital support staging. Bone marrow biopsy, cerebrospinal fluid analysis when indicated, and cytogenetics performed at reference laboratories such as the Mayo Clinic Molecular Diagnostics Laboratory underpin diagnostic algorithms endorsed by the National Cancer Institute and European LeukemiaNet.

Staging and Prognosis

Staging commonly follows the Lugano classification and Ann Arbor system, with prognostic indices such as the International Prognostic Index guiding risk stratification; these tools were developed through multicenter trials coordinated by cooperative groups including the European Organisation for Research and Treatment of Cancer and the Children's Oncology Group. Prognosis varies markedly: indolent follicular lymphoma cohorts reported by University of Texas MD Anderson show prolonged survival, whereas aggressive DLBCL outcomes have improved with regimens validated in trials by the Eastern Cooperative Oncology Group and the Groupe d'Etude des Lymphomes de l'Adulte. Biomarkers and PET response, studied in trials at Dana‑Farber Cancer Institute and Instituto Nacional de Cancerología, refine outcome prediction.

Treatment

Treatment strategies include chemoimmunotherapy (for example rituximab‑based regimens originating from work at Genentech and approved following trials by the Food and Drug Administration), targeted therapies (BTK inhibitors, PI3K inhibitors) developed by pharmaceutical collaborations with companies such as Janssen and Pharmacyclics, radiation therapy delivered at centers like Memorial Sloan Kettering, and hematopoietic stem cell transplantation performed at specialist units including Fred Hutchinson Cancer Center. Emerging approaches include CAR T‑cell therapy pioneered at the National Cancer Institute and clinical trials coordinated through networks such as the Alliance for Clinical Trials in Oncology and European Society for Blood and Marrow Transplantation. Palliative care integration, survivorship programs, and patient advocacy by organizations including Macmillan Cancer Support influence supportive management.

Epidemiology and Outcomes

Incidence and mortality patterns vary globally; population studies from the Surveillance, Epidemiology, and End Results Program, Eurocare, and Globocan document higher incidence in North America and parts of Europe compared with Asia and Africa, though regional registries at the Tata Memorial Centre and National Cancer Center Korea report shifting trends. Survival has improved over recent decades due to advances described in landmark trials from cooperative groups such as SWOG and CALGB and real‑world analyses from Kaiser Permanente and the National Health Service, yet disparities persist as shown in studies from the World Bank and United Nations reports. Ongoing surveillance by agencies like the Centers for Disease Control and Prevention and research funding from the Wellcome Trust aim to further reduce morbidity and mortality associated with these diverse lymphoid neoplasms.

Category:Lymphoma